Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
Hematological Oncology · 2026-03 · 44 (2)
DOI: 10.1002/hon.70186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, online erschienen am 15.03.2026. Verfasst von Tom Schlusemann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Radiotherapy. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiotherapy (RT) constitutes an important treatment modality in multiple myeloma (MM), traditionally used for the management of symptomatic osteolytic and extramedullary lesions. Objectives of RT are symptom alleviation and prevention of complications such as neurological deficits and pathological fractures. Over the past decade, systemic therapy (ST) for MM has undergone substantial advancements, notably with the incorporation of monoclonal antibodies in frontline regimens, as well as the emergence of bispecific antibodies and chimeric antigen receptor T‐cells (CAR‐T) for relapsed and refractory disease. These therapeutic innovations have introduced new clinical challenges and expanded the indications for RT, including its role as bridging therapy prior to CAR‐T therapy, salvage therapy following CAR‐T failure, and in the management of oligoprogressive and/or extramedullary disease. The integration of novel systemic agents prompts critical questions regarding synergistic interactions, feasibility, efficacy, and tolerability of combined RT and ST approaches. Herein, we present a literature review summarizing current evidence stratified by systemic treatment modalities, and discuss the clinical implications within the contemporary therapeutic landscape of MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
- Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
ORCID-Profile: Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Stefan Gravemeyer, Matthias Stelljes, Michael Oertel
Zitieren
APA
Schlusemann, T., Shumilov, E., Reinartz, G., Steike, D. R., Lohmann, S., Gravemeyer, S., Stelljes, M., Lenz, G., Eich, H. T., & Oertel, M. (2026). Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma. Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70186
Vancouver
Schlusemann T, Shumilov E, Reinartz G, Steike DR, Lohmann S, Gravemeyer S, et al. Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma. Hematological Oncology. 2026;44(2). doi:10.1002/hon.70186
BibTeX
@article{Schlusemann2026,
author = {Schlusemann, Tom and Shumilov, Evgenii and Reinartz, Gabriele and Steike, David Rene and Lohmann, Sebastian and Gravemeyer, Stefan and Stelljes, Matthias and Lenz, Georg and Eich, Hans Theodor and Oertel, Michael},
title = {Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {2},
doi = {10.1002/hon.70186}
}
EUVIMED